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Summary
Background Ascorbic acid reduced the severity of neuropathy in transgenic mice overexpressing peripheral myelin 
protein 22 (PMP22), a model of Charcot–Marie–Tooth disease type 1A (CMT1A) associated with the PMP22 duplication. 
However, in three 1-year trials, ascorbic acid had no beneﬁ t in human beings. We did a multicentre 2-year trial to test 
the eﬃ  cacy and tolerability of ascorbic acid in patients with CMT1A.
Methods Adult patients (aged 18–70 years) with symptomatic CMT1A were enrolled from nine centres in Italy and the 
UK, and were randomly assigned (1:1 ratio) to receive 1·5 g/day oral ascorbic acid or matching placebo for 24 months. 
The randomisation sequence was computer generated by block randomisation, stratiﬁ ed by centre and disease severity, 
and patients were allocated to treatment by telephone. The primary outcome was change in the CMT neuropathy score 
(CMTNS) at 24 months. Secondary outcomes were timed 10 m walk test, nine-hole peg test, overall neuropathy 
limitations scale, distal maximal voluntary isometric contraction, visual analogue scales for pain and fatigue, 36-item 
short-form questionnaire, and electrophysiological measurements. Patients, treating physicians, and physicians 
assessing outcome measures were masked to treatment allocation. Analysis of the primary outcome was done on all 
randomised patients who received at least one dose of study drug. This study is registered, numbers ISRCTN61074476 
(CMT-TRAUK) and EudraCT 2006-000032-27 (CMT-TRIAAL).
Findings We enrolled and randomly assigned 277 patients, of whom six (four assigned to receive ascorbic acid) withdrew 
consent before receiving treatment; 138 receiving ascorbic acid and 133 receiving placebo were eligible for analysis. 
Treatment was well tolerated: 241 of 271 patients (89% in each group) completed the study; 20 patients (nine receiving 
ascorbic acid) dropped out because of adverse events. Mean CMTNS at baseline with missing data imputed was 14·7 
(SD 4·8) in the ascorbic acid group and 13·9 (4·2) in the placebo group. Mean worsening of CMTNS was 0·2 (SD 2·8, 
95% CI –0·3 to 0·7) in the ascorbic acid group and 0·2 (2·7, –0·2 to 0·7) in the placebo group (mean diﬀ erence 0·0, 
95% CI –0·6 to 0·7; p=0·93). We recorded no diﬀ erences between the groups for the secondary outcomes at 24 months. 
21 serious adverse events occurred in 20 patients, eight in the ascorbic acid group and 13 in the placebo group.
Intepretation Ascorbic acid supplementation had no signiﬁ cant eﬀ ect on neuropathy compared with placebo after 
2 years, suggesting that no evidence is available to support treatment with ascorbic acid in adults with CMT1A.
Funding Telethon-UILDM and AIFA (Italian Medicines Agency) for CMT-TRIAAL, and Muscular Dystrophy Campaign 
for CMT-TRAUK.
Introduction
Charcot–Marie–Tooth disease (CMT), a disease for which 
no drug treatments are available, is the most common 
inherited neuromuscular disorder, and is characterised 
clinically by distal wasting, weakness, and sensory loss. 
The main subtype is type 1A (CMT1A), representing 
about half of all CMT cases. CMT1A is associated with an 
autosomal dominant duplication of the peripheral myelin 
protein 22 gene (PMP22), causing peripheral nerve 
demyelination and secondary axonal loss.1 Ascorbic acid 
reduced the severity of neuropathy in transgenic mice 
overexpressing PMP22, an animal model of human 
CMT1A, compared with untreated mice.2 Some clinical 
indicators improved during treatment, suggesting partial 
reversion of the phenotype. Ascorbic acid promotes 
myelination in vitro and possibly decreases PMP22 
expression.2,3 Evidence of eﬃ  cacy of ascorbic acid in the 
animal model prompted initiation of randomised 
controlled trials to test the eﬃ  cacy of ascorbic acid in 
patients with CMT1A.
Three trials assessing 1-year ascorbic acid treatment 
in patients with CMT1A have been completed. In a 
Dutch proof-of-concept trial, ascorbic acid had no eﬀ ect 
in ﬁ ve patients (aged 14–24 years) treated with 2 g/day 
compared with six patients on placebo (aged 
13–24 years).4 Findings of an Australian trial of 
42 children treated with an equivalent dose (30 mg/kg 
per day) failed to show a signiﬁ cant eﬀ ect on disease 
course compared with 39 children on placebo.5 Similarly, 
in a French trial of 179 adult patients treated with one of 
two doses of ascorbic acid (1 or 3 g/day) or placebo, 
ascorbic acid had no signiﬁ cant beneﬁ t.6
In the ﬁ rst two trials, motor conduction velocity of the 
median nerve was the primary outcome measure, 
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whereas the CMT neuropathy score (CMTNS) was the 
primary endpoint in the French trial. Two trials reported 
positive results from post-hoc analyses: in the Australian 
trial, ﬁ ve children treated with ascorbic acid had a large 
increase in motor conduction velocity in the median 
nerve;5 and in the French trial, the CMT examination 
score (CMTES, the clinical component [symptoms, signs] 
of the CMTNS) was signiﬁ cantly better in the 3 g/day 
group than in the other groups.6
As acknowledged by the authors themselves, these 
trials were both underpowered and too short.7 Moreover, 
ﬁ ndings obtained from post-hoc analyses should be 
interpreted with caution.8,9 Another crucial point is the 
choice of motor conduction velocity as the primary 
endpoint for the Dutch and Australian trials because, 
although axonal damage correlates with clinical 
progression, the correlation of motor conduction velocity 
with clinical progression is controversial.1 The only 
validated CMT-speciﬁ c outcome measure is the CMTNS, 
which is a composite of symptoms, signs, and motor and 
sensory action potential amplitudes of the ulnar or 
median nerve.10 The scale ranges from 0 (normal) to 36 
(worst). CMTNS progression rate was 0·68 points per 
year in a North American study of adults with untreated 
CMT1A11 and 0·5 points per year in the placebo group of 
the French trial.6
We did a phase 3, multicentre, placebo-controlled, 
double-blind randomised trial to assess the eﬃ  cacy and 
tolerability of chronic ascorbic acid treatment in patients 
with CMT1A in Italy (CMT-TRial Italian with Ascorbic 
Acid Long term [CMT-TRIAAL]) and the UK (CMT-TRial 
with Ascorbic acid United Kingdom [CMT-TRAUK]). In 
accordance with the consensus from the 136th European 
Neuromuscular Centre (ENMC) workshop that the 
CMTNS was the most appropriate primary endpoint for 
a trial of ascorbic acid in CMT1A, we chose the CMTNS 
as our primary outcome.7 Our secondary outcomes were 
also those suggested at this workshop.7,12
Methods
Patients
Detailed methods are reported in the published 
protocol.12 Patients with clinical and genetic diagnosis of 
CMT1A were enrolled from eight Italian hospitals and 
one UK hospital. Eligible patients were aged 18–70 years 
and had a CMTNS between 1 (excluding the electro-
physiological component) and 35 (including the 
electrophysiological component). Exclusion criteria 
were contraindications to ascorbic acid (nephrolithiasis, 
glucose-6-phosphate dehydrogenase deﬁ ciency, or iron 
overload), extra-dietary ascorbic acid supplementation 
in the 3 months before screening, limb surgery in the 
6 months before screening or planned for before ﬁ nal 
assessment, other causes of neuropathy (appropriate 
blood tests to exclude other causes of neuropathy were 
done at screening), or other clinically signiﬁ cant 
neurological or systemic diseases. At screening, women 
who were pregnant (patient’s statement, no pregnancy 
test required), breastfeeding, or planning to become 
pregnant during the study were not included. Women 
of childbearing age were advised to adopt contraception 
for the entire duration of the study. Women who became 
pregnant during the study were advised to stop treatment 
and notify the treating neurologist immediately. They 
were followed up regularly for the duration of the study 
to comply with the intention-to-treat design. The 
protocol was approved by the institutional review board 
at every site, and patients gave written informed consent 
before any study-related procedures.
Randomisation and masking
Patients were randomly assigned (1:1 ratio) to receive 
either 1·5 g ascorbic acid per day as three 0·5 g tablets 
(one at breakfast and two at dinner) or matching placebo, 
for 24 months. Ascorbic acid and placebo tablets had 
identical appearance, taste, and smell, were centrally 
blistered, packed, and labelled before being sent to the 
pharmacy of each study centre. The randomisation 
sequence was computer generated (by a pseudo-random 
number generator) by the randomisation unit 
(Neuroepidemiology Unit, Carlo Besta Neurological 
Institute, Milan, Italy), which was independent of the 
study. The sequence was known only by staﬀ  at the 
randomisation unit and the drug dispenser. Treatment 
was allocated centrally by telephone, and was stratiﬁ ed 
by centre and disease severity (CMTNS ≤10 vs >10, or 
CMTES ≤8 vs >8 if electrophysiological assessment was 
not done in the previous 3 months), with a block size of 
four (unknown to investigators) within each centre. The 
sequence was available in opaque sealed envelopes at 
every centre for emergency unmasking. Patients, treating 
physicians, and physicians assessing outcomes with 
clinical scales at baseline and during follow-up were 
masked to treatment allocation.
Procedures
We decided to give 1·5 g/day ascorbic acid, subdivided 
into two doses, on the basis of available pharmacokinetic 
data showing cellular saturation at doses of 100 mg/day,13 
the US Institute of Medicine recommendations of a 
tolerable upper intake level of 2 g/day,14 and the dose 
given to mice.2,12
After providing informed consent, patients underwent 
physical examination and laboratory testing at screening. 
Eligible patients returned at visit 1 (baseline) and were 
randomly assigned to treatment groups. Study visits were 
done at 6, 12, 18, and 24 months. Drug compliance, 
concomitant drug use, clinical scales, and 
electrophysiology were assessed at baseline and every 
6 months. Clinical scales assessed were CMTNS, 
maximal voluntary isometric contraction with a hand-
held myometer (Cit Technics, Haren, Netherlands) for 
distal arm movements (hand-grip and large three-point 
pinch) and leg movements (foot dorsiﬂ exion and plantar 
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ﬂ exion, by use of a stabilising device),18 overall neuropathy 
limitations scale,19 timed 10 m walk test, and nine-hole 
peg test.12 The 36-item short-form questionnaire (SF-36)15,16 
and pain and fatigue visual analogue scales12,17 were used 
at baseline and at 12 and 24 months.12 Safety was assessed 
by physical examination, adverse events, and serious 
adverse events every 6 months, and by laboratory tests at 
baseline and at 6, 12, and 24 months. 
At every visit, we took electrophysiological recordings 
from the motor ulnar, median, and peroneal nerves and 
the sensory ulnar nerve (non-dominant side, antidromic 
technique), and diﬀ erences between baseline and 
negative peak amplitudes of compound motor action 
potentials and sensory action potentials were assessed. 
Foot and hand skin temperature was checked and kept at 
32–34°C. Patients had laboratory tests of blood cell count, 
urine and its sediment, serum iron, total iron binding 
capacity, ferritin, and uric acid. Adherence was assessed 
by counting tablet returns every 3 months (including 
visits or contacts for drug delivery at 3, 9, 15, and 
21 months), and measurement of serum ascorbic acid 
concentrations by spectrophotometry20 every 6 months. 
Patients taking less than 80% of tablets were judged to be 
non-compliant.
The primary outcome was change in CMTNS at 2 years; 
for CMTNS, CMTES, and CMTNS subitems, data are 
presented at 12 and 24 months. Secondary outcomes 
were timed 10 m walk test, nine-hole peg test, overall 
neuropathy limitations scale, distal maximal voluntary 
isometric contraction, visual analogue scales for pain and 
354 patients assessed for eligibility
277 enrolled and randomly assigned
135 allocated to receive placebo142 allocated to receive ascorbic acid
133 received allocated intervention
2 did not receive
allocated intervention*
10 lost to follow-up
6 adverse events
2 pregnancy
1 gastralgia
2 diarrhoea
1 saccharine intolerance
3 withdrawal of consent
1 personal reasons
5 discontinued intervention and 
continued follow-up
5 adverse events
2 foot surgery
1 pregnancy
1 gastralgia
1 rectal bleeding  
12 lost to follow-up
7 adverse events
2 gastralgia
1 diarrhoea
1 gum disease
1 abdominal cramps
1 renal colic
1 lumbar surgery
3 withdrawal of consent
2 moved away from study area
3 discontinued intervention and 
continued follow-up
2 adverse events
1 abdominal cramps
1 vaginal cyst removed
1 personal reasons
4 did not receive
allocated intervention*
138 received allocated intervention
133 eligible for analysis138 eligible for analysis
77 excluded
22 other causes of neuropathy
12 genetic test not done or negative
10 history of renal colic or stones
10 other neurological disorder or major 
comorbidities
5 no signs of Charcot–Marie–Tooth disease
5 limb surgery
4 inadequate contraception
2 diagnosis of Charcot–Marie–Tooth disease
not conﬁrmed
2 unable to complete clinical scales
2 refused consent
1 hereditary haemochromatosis
1 ascorbic acid consumption during
3 months before enrolment
1 pregnancy
Figure 1: Trial proﬁ le
*Consent withdrawn before start of treatment.
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fatigue, SF-36, and electrophysiological measurements; 
for these outcomes, data are presented at 24 months. An 
independent data and safety monitoring committee 
supervised the safety and data quality, and did a masked 
interim analysis of the primary outcome measure at 
1 year, to conﬁ rm or disconﬁ rm study continuation.
Statistical analysis
On the basis of longitudinal data,11 we deﬁ ned a signiﬁ cant 
diﬀ erence as an improvement in CMTNS by 0·5 points 
or more in the ascorbic acid group compared with a 
worsening by 1 point in the placebo group at 24 months. 
Therefore, we expected a CMTNS of 13·0 in the ascorbic 
acid group and 14·5 in the placebo group at 24 months, 
with a common SD of 6·5.10 With these values, a two-
sided α of 0·05, and the assumption that 20% of patients 
would be lost to follow-up or discontinue treatment, we 
calculated that a sample of 272 patients (136 per group) 
would provide 90% statistical power to detect a signiﬁ cant 
diﬀ erence between the ascorbic acid and placebo groups.
The main analysis of the primary outcome included all 
randomised patients who took at least one dose of study 
treatment. We compared the study groups for the primary 
outcome by use of a linear mixed model for longitudinal 
data. To keep imputed values to a minimum, patients who 
stopped treatment were asked to attend scheduled follow-
up visits. For patients who were unavailable, missing data 
were imputed according to Rubin’s multiple imputation 
approach. A per-protocol analysis was done for the primary 
outcome and all secondary outcomes, and included 
patients who accomplished the outcome measures and 
were compliant with treatment (≥80% of tablets). For 
analysis of the primary outcome, we used the covariates 
baseline CMTNS, centre, age, and sex, and we also tested 
for ﬁ rst-order interaction terms (centre per treatment and 
sex per treatment). Between-group comparisons of 
proportions were done with Pearson’s χ² test or Fisher’s 
exact test, and comparisons of continuous variables were 
done with the Wilcoxon rank-sum test. Two-sided p values 
of less than 0·05 were judged to be signiﬁ cant; p values 
were not adjusted for multiple comparisons. Analyses 
were done with Stata (version 10.0) and SAS (version 9.2).
This study is registered, numbers ISRCTN61074476 
(CMT-TRAUK) and EudraCT 2006-000032-27 (CMT-
TRIAAL). CMT-TRIAAL and CMT-TRAUK shared a 
common protocol but have diﬀ erent names and 
registration numbers because funding was separate in 
Italy and the UK.
Ascorbic acid Placebo
Patients Mean (SD) Median (IQR) Patients Mean (SD) Median (IQR)
Women 78/138 (57%) ·· ·· 85/133 (64%) ·· ··
Age (years) 138 43·8 (13·7) 45·2 (32·1–54·5) 133 41·2 (12·4) 41·8 (31·8–51·3)
CMTNS
Total score 137 14·6 (4·9) 14·0 (11·0–18·0) 131 13·9 (4·3) 13·0 (11·0–17·0)
CMTES 138 9·2 (4·0) 8·5 (6·0–11·0) 133 8·6 (3·6) 8·0 (6·0–11·0)
Neurophysiological component 137 5·5 (1·6) 6·0 (5·0–7·0) 131 5·2 (1·6) 5·0 (5·0–6·0)
Timed 10 m walk test (s) 138 9·3 (5·1) 7·8 (6·8–9·7) 133 9·0 (5·4) 7·4 (6·5–8·7)
Nine-hole peg test (s; average for both sides) 137 24·8 (7·6) 23·1 (20·1–26·6) 131 23·4 (5·7) 22·1 (19·9–24·6)
Overall neuropathy limitations scale score 138 ·· 4·0 (2·0–4·0) 133 ·· 3·0 (2·0–4·0)
Maximal voluntary isometric contraction (N)
Handgrip 138 89·0 (45·6) 86·5 (51·0–115·0) 132 85·8 (38·8) 77·0 (58·5–110·5)
Large three-point pinch 138 67·4 (33·2) 64·0 (42·0–89·0) 132 65·2 (29·4) 63·0 (44·5–78·5)
Foot dorsiﬂ exion 137 67·9 (61·7) 60·0 (23·0–92·0) 131 62·8 (43·1) 56·0 (28·0–87·0)
Foot plantar ﬂ exion 138 104·3 (69·3) 90·0 (59·0–130·0) 131 97·0 (59·7) 84·0 (59·0–128·0)
Visual analogue scale score
Pain 137 3·7 (3·1) 4·0 (0·5–6·0) 133 3·6 (2·9) 3·0 (1·0–6·0)
Fatigue 137 5·0 (2·7) 5·0 (3·0–7·0) 133 4·8 (2·9) 5·0 (2·5–7·0)
SF-36 score
Physical functioning 133 61·3 (25·7) 60·0 (45·0–85·0) 132 62·9 (25·7) 65·0 (42·5–85·0)
Bodily pain 136 63·5 (28·4) 62·0 (41·0–100) 133 63·6 (25·8) 62·0 (41·0–84·0)
Energy 134 50·4 (21·3) 50·0 (35·0–65·0) 130 52·4 (21·6) 55·0 (40·0–65·0)
CMAP summatory (mV) 135 6·6 (3·9) 6·5 (3·8–9·3) 128 7·1 (4·1) 7·2 (4·3–9·2)
MCV (m/s)* 124 20·1 (4·8) 20·0 (17·1–23·0) 118 20·6 (4·4) 20·4 (17·6–23·3)
Higher CMTNS, CMTES, or overall neuropathy limitations scale score indicates more severe disease; higher visual analogue scale score indicates more severe symptom (pain 
or fatigue); higher SF-36 score indicates better quality of life. CMTNS=Charcot–Marie–Tooth neuropathy score. CMTES=Charcot–Marie–Tooth examination score. N=Newtons. 
SF-36=36-item short-form questionnaire. CMAP summatory=sum of compound motor action potentials of the three motor nerves (ulnar, median, and peroneal nerves). 
MCV=motor conduction velocity. *Mean from median and ulnar nerves.
Table 1: Demographic and clinical characteristics at baseline
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Role of the funding source
A representative of the main sponsor (Telethon Italy) 
attended meetings of the steering committee as non-
voting external participant. The study database is held by 
the Neuroepidemiology Unit, Carlo Besta Neurological 
Institute, Milan, Italy. The funding sources had no role in 
the study design, data collection, data analysis, data 
interpretation, preparation of the report, or the decision 
to submit for publication. The corresponding author and 
all coauthors had access to all data and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between March, 2006, and September, 2007, 277 of 
354 patients (78%) were deemed eligible and were 
randomly assigned, of whom six withdrew consent before 
receiving treatment; 138 assigned to receive ascorbic acid 
and 133 assigned to receive placebo were eligible for the 
main analysis (ﬁ gure 1). Demographic and clinical 
characteristics were balanced across treatment groups at 
baseline (table 1). Only one patient in the ascorbic acid 
group had a CMTNS of more than 30, indicating severe 
disease, ﬁ ve patients (three in the ascorbic acid group) 
had a CMTNS of more than 25, and two patients (one in 
each group) had a CMTNS of less than 5.
In the main analysis of the primary outcome with 
missing data imputed, mean CMTNS changed from 14·7 
(SD 4·8) at baseline to 14·9 (5·4) at 24 months in the 
ascorbic acid group, and from 13·9 (4·2) to 14·2 (4·4) in 
the placebo group (ﬁ gure 2A). Mean change in CMTNS 
from baseline to 24 months was 0·2 (SD 2·8, 95% CI 
–0·3 to 0·7) in the ascorbic acid group and 0·2 (2·7, 
–0·2 to 0·7) in the placebo group, with a mean between-
group diﬀ erence of 0·0 (95% CI –0·6 to 0·7; p=0·93; 
ﬁ gure 2B). Mean change in CMTNS from baseline to 
12 months was –0·1 (SD 2·4, 95% CI –0·5 to 0·3) in the 
ascorbic acid group and 0·2 (2·1, –0·2 to 0·5) in the 
placebo group, with a mean between-group diﬀ erence 
of 0·2 (95% CI –0·3 to 0·8; p=0·39). Data were missing 
for three patients at baseline (one on ascorbic acid vs two 
on placebo), 25 patients at each of 6 months (12 vs 13) and 
12 months (13 vs 12), 34 patients at 18 months (16 vs 18), 
and 26 patients at 24 months (12 vs 14). Findings of the 
per-protocol analysis of the primary outcome of CMTNS 
showed a worsening of disease in both the ascorbic acid 
and placebo groups at 24 months (table 2). CMTNS was 
higher in the placebo group than in the ascorbic acid 
group at both 12 and 24 months, with a mean between-
group diﬀ erence of 0·3 (95% CI –0·3 to 0·9; p=0·27) at 
12 months and 0·4 (–0·3 to 1·1; p=0·28) at 24 months.
In the prespeciﬁ ed multivariate analysis, ascorbic acid 
treatment had no signiﬁ cant eﬀ ect on the primary 
outcome (p=0·491), and had no interaction with sex 
(p=0·891) or centre (p=0·529; webappendix p 1). Greater 
CMTNS at baseline (p<0·0001), older age (p=0·005), 
and longer time from start of study (p=0·004) were 
associated with worse prognosis. Centre had a signiﬁ cant 
eﬀ ect (p=0·042): in a subgroup analysis, patients treated 
at the centres in Milan and the UK had a slightly better 
outcome, irrespective of treatment group, than did those 
treated at the remaining seven centres, but this 
diﬀ erence was signiﬁ cant only at 12 months (p=0·04). 
This marginal diﬀ erence, which was not signiﬁ cant at 
24 months, does not aﬀ ect interpretation of treatment 
eﬀ ect (webappendix p 1).
Findings of the per-protocol analysis of secondary 
outcomes showed no signiﬁ cant diﬀ erence between 
treatment groups for change in timed 10 m walk test, 
nine-hole peg test, overall neuropathy limitations scale, 
maximal voluntary isometric contraction, visual analogue 
scale scores for pain and fatigue, SF-36 scores, or electro-
physiological measurements (table 3). Furthermore, 
changes from baseline to 24 months were negligible in 
both groups. Foot dorsiﬂ exion seemed to be the most 
responsive measure with a mean worsening of more than 
10% (tables 1 and 3).
Overall, ascorbic acid treatment was well tolerated. 
15 patients (11%) in each treatment group discontinued 
treatment early, of whom six in the ascorbic acid group 
and ﬁ ve in the placebo group discontinued because of 
oral or gastrointestinal symptoms (ﬁ gure 1). 134 patients 
(97%) on ascorbic acid and 127 (95%) on placebo had 
drug adherence of more than 80%. 21 serious adverse 
events occurred in 20 patients, eight events in seven 
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Figure 2: Mean CMTNS (A) and mean change in CMTNS from baseline (B)
Analysis was done on all patients who were randomised and received at least 
one dose of study drug. Higher CMTNS indicates more severe disease. 
CMTNS=Charcot–Marie–Tooth neuropathy score. 
See Online for webappendix
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patients on ascorbic acid and 13 events in 13 patients on 
placebo: three pregnancies; 12 hospital admissions for 
surgery (four for foot surgery, three for haemorrhoids, 
and one each for disc herniation, gallbladder stones, 
hysterectomy, vaginal cyst removal, and tooth extraction); 
one diagnostic procedure (arteriography); and ﬁ ve 
hospital admissions for other reasons (depression, loss 
of consciousness, bronchitis, anaemia, and rectal 
bleeding). All serious adverse events were deemed to be 
unrelated to treatment, with the exception of one 
hospital admission owing to anaemia in a woman on 
placebo. In eight patients, two receiving ascorbic acid 
and six receiving placebo, a serious adverse event was 
the reason for discontinuation of intervention, of whom 
three patients (one receiving ascorbic acid and two 
receiving placebo) withdrew from the study. The most 
Ascorbic acid Placebo p value
Patients Mean change (95% CI) Patients Mean change (95% CI)
Timed 10 m walk test (s) 118 0·76 (0·08 to 1·44) 109 1·12 (–0·38 to 2·61) 0·81
Nine-hole peg test (s; average of both sides) 118 0·11 (–0·59 to 0·80) 106 0·85 (0·33 to 1·37) 0·07
Overall neuropathy limitations scale score* 118 0·11 (–0·07 to 0·29) 109 0·09 (–0·07 to 0·25) 0·99
Maximal voluntary isometric contraction (N)
Handgrip 118 –6·23 (–10·37 to –2·09) 107 –6·86 (–10·70 to –3·02) 0·83
Large three-point pinch 118 –2·00 (–4·83 to 0·83) 107 –3·62 (–7·19 to –0·05) 0·97
Foot dorsiﬂ exion 118 –9·19 (–16·26 to –2·12) 107 –9·81 (–14·30 to –5·33) 0·25
Foot plantar ﬂ exion 118 –5·78 (–16·34 to 4·78) 107 –2·69 (–11·74 to 6·35) 0·89
Visual analogue scale score
Pain 118 0·31 (–0·15 to 0·76) 107 0·59 (0·05 to 1·13) 0·32
Fatigue 118 –0·33 (–0·82 to 0·17) 107 0·03 (–0·52 to 0·59) 0·41
SF-36 score
Physical functioning 115 –0·43 (–3·38 to 2·52) 106 –1·05 (–3·97 to 1·88) 0·81
Bodily pain 117 –1·27 (–5·42 to 2·87) 107 –0·85 (–5·62 to 3·93) 0·74
Energy 112 1·21 (–1·97 to 4·38) 104 –0·34 (–3·89 to 3·21) 0·31
CMAP summatory (mV) 113 0·47 (0·01 to 0·92) 104 0·24 (–0·31 to 0·79) 0·43
MCV (m/s)† 107 0·38 (–0·06 to 0·82) 98 0·61 (0·15 to 1·06) 0·88
Higher overall neuropathy limitations scale score indicates more severe disease; higher visual analogue scale score indicates more severe symptom (pain or fatigue); higher 
SF-36 score indicates better quality of life. N=Newtons. SF-36=36-item short-form questionnaire. CMAP summatory=sum of compound motor action potentials of the three 
motor nerves (ulnar, median, and peroneal nerves). MCV=motor conduction velocity. *Data are median change (95% CI). †Mean from median and ulnar nerves.
Table 3: Change in secondary outcomes from baseline to 24 months (per-protocol population)
Ascorbic acid Placebo p value
Patients Mean change (SD, 95% CI) Patients Mean change (SD, 95% CI)
CMTNS, total score
12 months 122 –0·1 (–0·5 to 0·3) 116 0·2 (–0·2 to 0·6) 0·27
24 months 118 0·1 (–0·4 to 0·6) 109 0·5 (0·0 to 1·0) 0·28
CMTES
12 months 122 0·2 (–0·2 to 0·5) 116 0·2 (–0·1 to 0·6) 0·52
24 months 118 0·2 (–0·3 to 0·6) 109 0·5 (0·1 to 0·9) 0·17
CMTNS, symptoms
12 months 122 0·0 (–0·2 to 0·3) 116 0·1 (–0·1 to 0·3) 0·68
24 months 118 0·1 (–0·2 to 0·3) 109 0·1 (–0·2 to 0·3) 0·87
CMTNS, signs
12 months 122 0·1 (–0·2 to 0·4) 116 0·2 (–0·1 to 0·5) 0·44
24 months 118 0·1 (–0·2 to 0·4) 109 0·5 (0·2 to 0·7) 0·11
CMTNS, neurophysiological component
12 months 122 –0·3 (–0·5 to –0·1) 116 0·0 (–0·3 to 0·2) 0·06
24 months 118 –0·1 (–0·3 to 0·1) 109 –0·1 (–0·3 to 0·2) 0·84
Higher CMTNS or CMTES indicates more severe disease. CMTNS=Charcot–Marie–Tooth neuropathy score. CMTES=Charcot–Marie–Tooth examination score. 
Table 2: Change in CMTNS, CMTES, and CMTNS subitems from baseline to 12 and 24 months (per-protocol population)
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common solicited adverse events were gastrointestinal 
disturbances, which occurred with similar frequency in 
both groups (web appendix pp 2–7).
Mean serum concentrations of ascorbic acid at 
baseline were similar in the two study groups: 
38·8 μmol/L (SD 29·3, n=88 patients) in the ascorbic 
acid group, and 34·3 μmol/L (19·8, n=87) in the placebo 
group (p=0·390). Mean serum concentrations of 
ascorbic acid in patients receiving ascorbic acid were 
signiﬁ cantly increased at 24 months (49·1 μmol/L 
[SD 23·0], n=56) compared with at baseline (p=0·024), 
and compared with patients receiving placebo at 
24 months (37·0 μmol/L [SD 16·2], n=56; p=0·004).
Discussion
In this 2-year randomised trial of high-dose ascorbic 
acid in the largest cohort of adults with CMT1A so far, 
we identiﬁ ed no evidence that ascorbic acid is eﬃ  cacious 
for the primary outcome, CMTNS, or for several 
prespeciﬁ ed secondary outcomes, which included 
impairment, activity limitation, and quality-of-life 
measures (panel).
Our ﬁ ndings conﬁ rm and expand the results of the 
Dutch,4 Australian,5 and French6 1-year studies of ascorbic 
acid in CMT1A. These studies were limited by their 
statistical power and, in two studies, by the use of motor 
conduction velocity as the primary outcome.4,5 We 
addressed these issues by choosing the CMTNS as our 
primary outcome,7 and by powering our trial in accordance 
with the predicted change in CMTNS from Shy and 
colleagues’ study11 (1·4 points in 24 months). The most 
likely interpretation of our results is that ascorbic acid is 
not eﬃ  cacious in CMT1A. Three less likely interpretations 
are that the study was not long enough, the dose of 
ascorbic acid was insuﬃ  cient, or the eﬀ ect was too small 
to be detected by the outcome measures used.
With respect to study length, an unexpected ﬁ nding 
was that disease progression was slower than was 
predicted from previous retrospective observational 
studies.11,22 Mean CMTNS worsened by 0·46 points in 
24 months (ie, 0·23 points per year) in the placebo group 
(per-protocol analysis), which is three times lower than 
that reported in the longitudinal study by Shy and 
colleagues (0·68 points per year),11 lower than that in the 
placebo group of the French trial (0·5 points per year),6 
and slightly lower than that reported in a longitudinal 
study by Verhamme and colleagues (1·5 points worsening 
of an adapted CMTNS in 5 years).22 However, the studies 
by Shy11 and Verhamme22 and their colleagues were partly 
retrospective, and therefore might not be directly 
comparable with our study. We feel that our large series 
is highly representative of the adult population with 
CMT1A treated at neurological centres.
The slow progression of CMTNS in adults with CMT1A 
raises the possibility that we might have missed a small 
eﬀ ect of ascorbic acid in a 2-year study. Increasing the 
trial length in adults would be very diﬃ  cult and perhaps 
impractical, but improved outcome measures could help. 
Participants of an ENMC workshop in 2009 agreed that 
some CMTNS components are not sensitive, and a 
modiﬁ ed CMTNS is in development.21 Furthermore, in 
our study, results indicated that development of myometry 
(especially foot dorsiﬂ exion) as an outcome measure 
might be useful. The disease starts in childhood, so 
treatment eﬀ ects might be more easily detected in 
children than in adults in future trials. However, existing 
evidence suggests that use of CMTNS is not appropriate 
in children younger than 10 years, and a paediatric 
CMTNS is in development.21
With respect to the dose of ascorbic acid, we chose a 
dose that was about twice or thrice the equivalent dose 
given to mice (which synthesise ascorbic acid)2 and was 
expected to achieve maximum and steady plasma 
concentrations with a low risk of side-eﬀ ects.12 This 
dose was well tolerated in our study. Although we feel 
that the dose we used should have been suﬃ  cient to 
detect eﬃ  cacy, Micallef and colleagues6 recorded weak 
evidence of an eﬀ ect of 3 g/day ascorbic acid in the 
French trial, only because CMTES was signiﬁ cantly 
better in the 3 g/day group than in the other group. 
This post-hoc ﬁ nding should be interpreted with 
caution, and, notably, the most substantial contribution 
to the diﬀ erence was from the CMTNS sensory 
component, which is the least reliable component.6,10 
Moreover, ﬁ ndings of pharmacokinetic studies suggest 
that doses of higher than 500 mg/day do not substantially 
increase cellular concentrations because of saturation 
and tight metabolic control,13 and, in the French trial,6 
dose increase from 1 to 3 g/day produced only a slight 
Panel: Research in context
Systematic review
We searched the Cochrane Central Register of Controlled Trials 
(CENTRAL) on the Cochrane Library (issue 1, 2011), Medline 
(1985–2011), Embase (1985–2011), and the trial registries 
ClinicalTrials.gov and Current Controlled Trials with the search 
terms “peripheral neuropathy”, “hereditary neuropathy”, 
“Charcot–Marie–Tooth”, “HMSN”, “ascorbic acid”, and 
“vitamin C”. We also obtained information from 
handsearching of references in selected articles and conference 
proceedings, and from contacts with other investigators. We 
identiﬁ ed seven studies assessing the eﬃ  cacy of ascorbic acid 
in patients with CMT1A.21 Three are published randomised 
controlled trials assessing 1-year treatment with ascorbic acid 
treatment versus placebo, and ascorbic acid did not have a 
treatment eﬀ ect in any of the trials.4–6
Interpretation
We identiﬁ ed no evidence of eﬃ  cacy of 1·5 g/day ascorbic 
acid in a large cohort of patients with CMT1A across a 
treatment period of 2 years. We feel that this study adds 
strong weight to existing evidence that ascorbic acid is not 
eﬃ  cacious in CMT1A.
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increase in plasma concentrations. Finally, the US 
Institute of Medicine has set a tolerable upper intake 
level of 2 g/day, above which the risk of gastrointestinal 
and renal side-eﬀ ects increases. We judged that our 
chosen dose was a good compromise by resulting in 
near saturation of plasma and cellular concentrations 
without risk of frequent side-eﬀ ects, which could also 
unmask treatment. We await with interest the results of 
the continuing US study of 4 g/day ascorbic acid 
(NCT00484510)21 and also ﬁ ndings of tolerance to 
treatment because 5 g/day was poorly tolerated in a 
small study.23
With respect to the size of the eﬀ ect of ascorbic acid, if 
the eﬀ ect is so small that only a biomarker can detect it, it 
would be unlikely to be clinically signiﬁ cant in a short-
term study but might be important in the long term. To 
address this issue, we are studying PMP22 expression in 
skin biopsy samples24 before and after treatment in a 
subgroup of patients from our study.
Findings of this study suggest that ascorbic acid is not 
eﬃ  cacious in adults with CMT1A. We have shown that a 
rigorous international randomised trial can be done in 
CMT. The use of the CMTNS should also provide the 
opportunity for meta-analysis of the eﬃ  cacy of ascorbic 
acid in CMT1A, when data from other trials that use this 
endpoint become available. Moreover, the data obtained 
from all these trials will provide unique information 
about the natural history of CMT1A.
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